News

AnnJi is attending BIO-ASIA 2020

AnnJi is attending BIO-ASIA 2020! AnnJi is honored to be invited to present our company and pipeline in BIO-ASIA 2020. We are seeking novel drug candidates in that could enrich our pipeline, as well as product development partners for the global market.  Please...

Positive Feedback of AJ302 from US-FDA reviewers

Positive Feedback of AJ302 from US-FDA reviewers AnnJi received positive feedback from US-FDA to submit an IND to initiate phase 1 clinical trial of AJ302 for the treatment of chemotherapy induced neuropathy. AJ302 is a first-in-class HDAC6 selective inhibitor that...

R&D Update

AJ302

AJ302

AJ302    AJ302 is a first-in-class HDAC6 inhibitor under development for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy. Phase 1 clinical trial of AJ302 will be initiated in early 2021.  AJ302 was selected among...

AJ503

AJ503

AJ503   AJ503 is an oral program of PDE4 inhibitor under candidate selection for the treatment for systemic inflammatory disorders such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, and other inflammatory bowel disease (IBD).  

AJ303

AJ303

AJ303   AJ303 is a novel compound under development for the treatment of idiopathic pulmonary fibrosis (IPF). It decreased IPF-related inflammatory cytokines, such as IL-6, MCP1, and GM-CSF in vitro, that delays the progression of pulmonary fibrosis in...

AJ502

AJ502

AJ502   AJ502 is a novel, potent, and selective PDE4 inhibitor that has good skin permeating characteristics. Topically administered AJ502 showed efficacy in IMQ-induced psoriasis and PMA-induced atopic dermatitis in the animal models superior to that of marketed...

News Center

News

R&D Pipeline

Journal

Article

Contact

We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.

+886-02-2365-5677

info@ajpharm.com

B405, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

12 + 1 =